Linderane

Catalog No.S9229 Batch:S922901

Technical Data

Formula	C₁₅H₁₆O₄
Molecular Weight	260.29	CAS No.	13476-25-0
Solubility (25°C)*	In vitro	DMSO	52 mg/mL (199.77 mM)


* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

Linderane, isolated from Lindera strychnifolia vill., is an indirect PDE3 activator and possesses multiple biological effects, including superoxide anion radical-scavenging and antioxidative activity and protective activity against gastritis, gastric ulcers and backache.

Targets

PDE3 ^[1]

In vitro

Linderane inhibits gluconeogenesis by activating hepatic PDE3 in rat primary hepatocytes. It reduces phosphoenolpyruvate carboxykinase (Pck1) and glucose-6-phosphatase (G6pc) gene expression, and decreases intracellular cAMP concentration and CREB phosphorylation in rat primary hepatocytes under both basal and forskolin-stimulated conditions. Linderane also increases total PDE and PDE3 activity but not PDE4 activity in rat primary hepatocytes. Linderane indirectly activated PDE3 through extracellular regulated protein kinase 1/2 (ERK1/2) and signal transducer and activator of transcription 3 (STAT3) activation^[1].

In vivo

Linderane improved glucose and lipid metabolism after chronic oral administration in ob/ob mice^[1].

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines rat primary hepatocytes Concentrations 2.5, 5, 10, 20 μM Incubation Time 1.5 h Method Rat primary hepatocytes are incubated in serum-free, glucose-free Dulbecco's modified Eagle's medium (DMEM) supplemented with metformin (500 μM) or different doses of linderane for 1.5 h, followed by 4 h of incubation in the presence or absence of gluconeogenic substrates (2 mM sodium pyruvate, plus 20 mM sodium lactate) with or without the stimulation of forskolin (20 μM). Medium is collected to determine glucose production.
Animal Study:^{^[1]}	Animal Models C57BL/6J mice (male, 8–9 weeks) Dosages 50 mg/kg Administration oral

Cell Assay:^{^[1]}

Cell lines
rat primary hepatocytes
Concentrations
2.5, 5, 10, 20 μM
Incubation Time
1.5 h
Method
Rat primary hepatocytes are incubated in serum-free, glucose-free Dulbecco's modified Eagle's medium (DMEM) supplemented with metformin (500 μM) or different doses of linderane for 1.5 h, followed by 4 h of incubation in the presence or absence of gluconeogenic substrates (2 mM sodium pyruvate, plus 20 mM sodium lactate) with or without the stimulation of forskolin (20 μM). Medium is collected to determine glucose production.

Animal Study:^{^[1]}

Animal Models
C57BL/6J mice (male, 8–9 weeks)
Dosages
50 mg/kg
Administration
oral

References

[1] Xie W, et al. Front Pharmacol. 2018, 9:476.

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.